March 06, 2008
Gilead Appoints Dr. John J. Toole as Senior Vice President, Corporate Development
FOSTER CITY, Calif.--(BUSINESS WIRE)--March 6, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) announced today the appointment of John J. Toole, MD, PhD, to the position of Senior Vice President, Corporate Development. In this role, Dr. Toole will be responsible for setting the strategy for and managing the company's business development and alliance management activities. Dr. Toole will report to John F. Milligan, PhD, Gilead's Chief Operating Officer and Chief Financial Officer.
Dr. Toole joined Gilead in 1990 and most recently held the role of Senior Vice President, Clinical Research. Prior to joining Gilead, he was a founding researcher of Genetics Institute in Cambridge, Massachusetts. He also completed postdoctoral fellowships at Harvard Medical School and the Massachusetts Institute of Technology. Dr. Toole received his MD from Stanford University School of Medicine and his PhD from the State University of New York at Buffalo.
"In the nearly 18 years Jay has been with Gilead, he has led and managed initiatives across the spectrum of the drug development process," said Dr. Milligan. "His broad knowledge of research and clinical development will be instrumental as we evaluate opportunities to partner with other companies to bring forward more new products for patients in need."
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.